Case Reports

MELAS SYNDROME IN TWO IRANIAN CHILDREN

M. GHOFRANI, * M.D., AND G.R. ZAMANI, ** M.D.

From the *Dept. of Child Neurology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, and the **Department of Child Neurology, Ahwaz University of Medical Sciences, Ahwaz, I.R. Iran.

ABSTRACT

MELAS syndrome is a mitochondrial disorder with progressive nature, because adequate treatment is not available. Diagnosis of this mitochondrial disorder depends initially on clinical suspicion, which is strengthened by additional metabolic evidence of impaired oxidative metabolism such as high serum or C.S.F. lactate levels and confirmed by demonstration of mitochondrial abnormalities in muscle biopsy. Here we present the clinical course and management of two children with MELAS syndrome who exhibited progressive neurologic deterioration.


Keywords: MELAS syndrome, mitochondrial disorders.

INTRODUCTION

The MELAS syndrome (mitochondrial abnormality, encephalopathy, lactic acidosis and stroke-like episodes) is a progressive neurodegenerative disease which can be inherited maternally or occur sporadically. The molecular pathology which underlies this syndrome is a point mutation on the mitochondrial genome leading to deficiency in one or more respiratory chain enzymes, most commonly complex I (NADH Co-enzyme Q reductase). Affected children are normal at birth and may develop normally until late childhood. The cardinal neurologic features are recurrent attacks of prolonged migraine headaches, vomiting, encephalopathy, and seizures with sudden onset of focal neurologic deficits. Neurological abnormalities are initially intermittent but later become constant, leading to coma and death.

Case 1

M.H. was a 4 years and 10 months old boy when admitted in the Child Neurology Ward at Mofid Children's Hospital in Tehran for drowsiness, seizures and right-sided weakness. His parents complained of episodic attacks of abdominal pain, vomiting and loss of consciousness in their child since 2 years ago, which repeated every 1 to 4 weeks, each episode lasting 24 to 48 hours. Parents also reported complex partial seizures on several occasions. After the last episode which was 20 days before admission, the patient became speechless and unambulatory. He had been treated for abdominal migraine and cyclic vomiting without any benefit during the past two years.

The patient was from a nonconsanguinous marriage and his birth history was uneventful. He also had normal psychomotor development until his recent attack. His growth milestones were also appropriate for his age. Neurological examination revealed the patient to be confused, speechless and unambulatory because of weakness in both sides
MELAS Syndrome

with left sided predominance. Laboratory evaluation exhibited an elevated lactate level of 2.5 mmol/L (normal range: 0.5-2 mmol/L) and increased liver enzymes [SGPT 119 IU/L (normal range: 5-40 IU/L) and SGOT 180 IU/L (normal range: 5-40 IU/L)]. Blood gases, glucose level, lipid profile, serum ammonia, muscle enzymes, blood coagulation factors, and cardiovascular evaluation were all within normal limits.

A brain MRI showed at least two areas of infarct in the temporal and temporoparietal regions with concomitant brain edema. Electromicroscopic muscle biopsy revealed abnormal mitochondrial proliferation and structure, suggestive of a mitochondrial myopathy. DNA analysis for mitochondrial DNA defect and biochemical study of oxidative phosphorylation complex enzymes were not available.

Considering the above clinical features and lab findings, our diagnosis was MELAS syndrome for this patient. We initiated treatment with steroids (dexamethasone), an anticonvulsant (phenytoin in the acute phase and then switching to carbamazepine when liver function tests decreased to normal limits), carnitine, vit. B (B complex, biotin), vitamin C, vitamin K, short term prednisolone and different anticonvulsant drugs with best response to Mogadon.

With this treatment, the patient showed improvement in locomotion, coginiton and seizure control during the first 6 months. However, gradually myoclonic jerks became refractory by the time of this writing.

18 months having elapsed on this treatment, the patient is still ambulatory but suffers from spasticity, difficulty in locomotion and intractable myoclonic jerks.

DISCUSSION

Pavlakis and his colleagues were first to describe two cases of MELAS syndrome and reviewed 9 other reported cases classically in 1984.6

As mentioned, the molecular pathology concerning this syndrome is a point mutation on the mitochondrial genome, most commonly at nucleotide number 3243 encoding the tRNA for leucine.2,4

In about less than 10 percent of cases the mutation is at positions 3271 to 3302; however, the affected gene product with each of these mutations is the tRNA for leucine.

In about 90 percent of pedigrees, family history is compatible with maternal transmission but in 10 percent of cases no familial transmission is found, as in our cases.3

Patients are usually asymptomatic in infancy and have normal early development for the first several years. However, some may display muscle weakness, fatigueability and myalgia before presentation of MELAS.3,5

Neurological symptoms begin between infancy and late childhood. These children develop short stature and recurrent epileptic seizures which may be focal, generalized or myoclonic. They also suffer prolonged migraine-like attacks of headaches with vomiting, which are prominent in some patients. In the wake of seizures or headaches, the patient abruptly develops stroke-like episodes.

Hemiparesis can alternate from side to side. Repeated infarctions lead to gradual decline of motor, sensory and cognitive functions. There is usually a history of dementia, dysarthria and progressive auditory and visual impairment.
Most patients eventually become deaf, blind and bedridden secondary to multiple strokes. A progressive myoclonic seizure can appear late in the course of the illness.

Systemic symptoms may result from cardiac, renal or endocrine involvement. The prognosis for patients with the full syndrome is dismal and death usually occurs a few years from onset.

Laboratory findings of MELAS syndrome are variable. Most patients present with elevation of lactate and pyruvate in the blood and CSF. Lactic acidosis is an inconsistent feature that may become symptomatic intermittently. CSF proteins may be elevated. Neuroimaging may show hypodensity and swelling of the cortex in multiple areas with a predilection for parieto-occipital regions, as we observed in our 2 reported cases.

Calcium deposits may also be found in the basal ganglia, particularly in the globus pallidus.

Hypoperfusion in the areas of infarct can be detected by SPECT when MRI or CT findings are normal. Brain MRI reveals the lesions more precisely than CT scan and may show cerebellar lesions which could not be detected on CT scan.

The mechanism of the stroke-like episodes is still unknown, and neuropathological studies show necrotic foci in the cortex.

The point mutation can be demonstrated in blood or muscle in mildly symptomatic or asymptomatic relatives. Blood DNA can be used to diagnose the mitochondrial deletion. This technique is especially useful in children in whom mutant mitochondrial levels in the blood are higher in relation to those in muscle.

Many cases of MELAS syndrome have an isolated complex I (NADH Q reductase) deficiency in biochemical studies of muscle mitochondria. However, multiple defects of the respiratory chain affecting complex I, III and especially IV have been documented. Enlargement and proliferation of mitochondria as a result of impaired respiration usually but not always show ragged red fibers in electronmicroscopic study of the muscle biopsy.

Unfortunately, treatment for mitochondrial disorders remains very limited. Many agents have been given to affected individuals as therapeutic trials but their beneficial effects are not long lasting. Potential strategies include correction of the metabolic milieu and avoiding exacerbating situations that lead to further compromise of mitochondrial function. This can be achieved by rapid treatment of infection, fever and avoidance of fasting and strenuous exercise.

1. Frequent or high caloric intake may be necessary to avoid the catabolic state.
2. Drugs to avoid are those that inhibit mitochondrial protein synthesis (e.g., tetracyclines, chloramphenicol), sequester carnitine (valproic acid) and inhibit the respiratory chain (barbiturates, phenytoin).
3. Removal of reactive oxygen with antioxidants (e.g., vit. C, vit. E, lipoic acid).
4. Replacement of products missing because of enzyme deficiency (complex I): sodium succinate 2g/daily and cofactor precursors such as thiamine (vit. B) 250 mg/daily, riboflavin (B) 100 mg/daily, biotin 5 mg bid and coenzyme Q10, 120 mg/daily, that function as part of the respiratory chain complex.
5. Low-dose synthetic steroids (prednisolone or methylprednisolone) have been found beneficial in improvement of systemic and encephalopathic symptoms of patients, including better seizure control, strengthening muscle force and lowering lactate and pyruvate levels. Sodium dichloro-acetate 50 mg/kg/d orally every 12 hours has also been suggested to activate residual mitochondrial oxidative enzyme activity and decreasing serum lactate levels, especially in patients with severe lactic acidosis. Using this agent (DCA) in the second case, our patient complained of loss of energy and feeling bad. Carnitine 50-100 mg/kg/d is another product that is recommended to be administered to patients with respiratory chain enzyme deficit who develop secondary carnitine deficiency.

**CONCLUSION**

The knowledge of mitochondrial disease is still very new, and the recent growth of information suggests that the relevance may be much greater than current clinical diagnostic tools permit us to recognize.

The majority of palliative therapies should be viewed as temporary rather than permanent solutions. Our understanding of treatment options are woefully inadequate. For example, we don’t know how to get rid of damaged mitochondria or how to restore their function. Efforts to develop gene therapy through substitution of a functional gene for a deficient one is the most important and promising area of continuing investigations.

**REFERENCES**

MELAS Syndrome